Marker Therapeutics, Inc. (NASDAQ:MRKR) Short Interest Down 35.5% in February

Marker Therapeutics, Inc. (NASDAQ:MRKR) saw a significant decline in short interest in the month of February. As of February 15th, there was short interest totalling 149,800 shares, a decline of 35.5% from the January 31st total of 232,100 shares. Approximately 2.1% of the company’s shares are sold short. Based on an average daily volume of 77,600 shares, the days-to-cover ratio is presently 1.9 days.

Marker Therapeutics Stock Performance

Shares of NASDAQ:MRKR traded down $0.08 during trading on Monday, hitting $1.45. The company’s stock had a trading volume of 17,560 shares, compared to its average volume of 71,691. The business has a 50 day moving average price of $2.26 and a two-hundred day moving average price of $3.00. Marker Therapeutics has a fifty-two week low of $1.44 and a fifty-two week high of $5.99.

Insider Buying and Selling at Marker Therapeutics

In other news, major shareholder Enterprise Associates 16 New bought 554,250 shares of the business’s stock in a transaction on Monday, December 23rd. The shares were bought at an average price of $3.20 per share, with a total value of $1,773,600.00. Following the completion of the transaction, the insider now directly owns 1,625,678 shares in the company, valued at $5,202,169.60. This trade represents a 51.73 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Steve Elms bought 11,085 shares of the business’s stock in a transaction on Monday, December 23rd. The stock was purchased at an average cost of $3.20 per share, for a total transaction of $35,472.00. Following the transaction, the director now owns 325,370 shares of the company’s stock, valued at $1,041,184. This trade represents a 3.53 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 14.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Marker Therapeutics

Institutional investors have recently modified their holdings of the business. Invst LLC acquired a new position in shares of Marker Therapeutics in the third quarter worth $56,000. Millennium Management LLC acquired a new position in shares of Marker Therapeutics in the fourth quarter worth $50,000. Northern Trust Corp grew its stake in shares of Marker Therapeutics by 66.9% in the fourth quarter. Northern Trust Corp now owns 54,156 shares of the company’s stock worth $168,000 after acquiring an additional 21,703 shares in the last quarter. NEA Management Company LLC grew its stake in shares of Marker Therapeutics by 51.7% during the fourth quarter. NEA Management Company LLC now owns 1,625,678 shares of the company’s stock worth $5,056,000 after purchasing an additional 554,250 shares in the last quarter. Finally, Alyeska Investment Group L.P. acquired a new position in shares of Marker Therapeutics during the fourth quarter worth $2,847,000. Institutional investors and hedge funds own 22.39% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Brookline Capital Management upgraded shares of Marker Therapeutics to a “strong-buy” rating in a research note on Monday, February 10th.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.